account_id none on file
legal_name Mesa Laboratories Inc /Co/
ticker MLAB
cik 724004
domain mesalabs.com
linkedin_company_url https://www.linkedin.com/company/mesa-laboratories-inc
entry_point_account_id none on file
name Mesa Laboratories Inc.
exchange Nasdaq
sector Industrials
hq Lakewood, CO, United States
sector index/company/sector/industrials/
calls 0 filings 7 executives 3 family 0
why_nownone on file
callsnone on file
filings
We strive to maintain our profitability by improving the effectiveness of our sales force, by continuing to pursue cost reduction initiatives, and by taking a long-term strategic approach to investments in our business that we believe will support future commercial success.
filing / Aug 10, 2026 / receipt
Research and development expense decreased 5.2% for the three months ended June 30, 2026 compared to the prior year period, primarily due to lower personnel costs resulting from cost-saving initiatives implemented during the second quarter of the prior fiscal year.
filing / Aug 10, 2026 / receipt
Directors are also reimbursed for expenses incurred in connection with their service as directors, including travel expenses for Board and committee meetings.
filing / Jul 22, 2026 / receipt
Board Biographies." Lyndsey Crennen was appointed Chief Accounting Officer in June 2026. 32 Table of Contents Executive Summary Business and Financial Summary In fiscal year 2026, Mesa operated in a dynamic environment characterized by regulatory and policy shifts as well as ongoing macroeconomic challenges.
filing / Jul 22, 2026 / receipt
Crennen was appointed Chief Accounting Officer in June 2026. (5) Dr. Kadia was appointed Director, President and CEO in April 2026.
filing / Jul 22, 2026 / receipt
Non-GAAP adjusted operating income excluding non-recuring items has been further adjusted to exclude items such as costs associated with our CEO transition, acquisition and integration costs, and corporate restructuring initiatives.
filing / Jul 22, 2026 / receipt
AOI was adjusted to exclude certain non-recurring expenses, including costs associated with our CEO transition and corporate restructuring initiatives, resulting in an adjusted AOI of $63.5 million during fiscal year 2026 and achievement of 175% of target levels for this performance metric.
filing / Jul 22, 2026 / receipt
executives
| John V. Sakys | Chief Financial Officer | - | receipt |
| Lyndsey Crennen | Corporate Controller | receipt | |
| Tony Tripeny | director | - | receipt |
familynone on file
upcoming
changes
| 2026-03-09 | President and Chief Executive Officer, departed | sec_8k |
| 2022-11-04 | director, appointed | sec_8k |
| 2017-09-01 | Chairman of the Board, departed | sec_8k |
| 2015-04-10 | director, retiring | sec_8k |
| 2012-12-04 | Chief Financial Officer, appointed | sec_8k |
| 2012-07-10 | Executive Vice President, departed | sec_8k |
mcp_package_hint
slug mesa-laboratories-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$